Boehringer Ingelheim has bought Swiss biotech AMAL Therapeutics, a company focused on cancer immunotherapy and cancer vaccines.
AMAL’s lead candidate, a stage IV colorectal cancer vaccine ATP128, is set to begin its first in-human trials later this month.
AMAL is headquartered on the medical campus of the University of Geneva. The biotech is a spin-out from the Swiss university which was backed by both corporate and institutional investors which include Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds.